Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesUnorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient
Pediatric Pulmonology, 04/13/09
Máiz L et al. - Staphylococcus aureus is a significant cause of pulmonary colonization in cystic fibrosis (CF) patients. The optimal strategy of therapy in chronically infected patients with this pathogen is not yet established. The authors report a successful long-term aerosolized ampicillin treatment of a 14-year-old girl with chronic symptomatic S. aureus lung infection.
Related Articles
Vitamin D supplementation for cystic fibrosis
Cochrane Reviews, 10/28/09
Relevance Score: 69%
Genetic Risk Factor for Liver Disease for Patients With Cystic Fibrosis
Gastroenterology, 10/27/09
Relevance Score: 69%
Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial
Inspire, 10/16/09
Relevance Score: 69%
Pulmonary nocardiosis in cystic fibrosis
Journal of Cystic Fibrosis, 10/07/09
Relevance Score: 69%
Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation
European Respiratory Journal, 10/23/09
Relevance Score: 68%
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor